Nuvation Bio vs Urogen Pharma
Urogen Pharma is the larger business, with $110m of revenue in fiscal 2025 against $62.9m for Nuvation Bio (1.7 times as much). Nuvation Bio grew faster (699.0% against 21.4%). Urogen Pharma kept more of each dollar of sales as profit: a net margin of -139.8% against -325.3%.
| Latest fiscal year | Nuvation BioNUVB, 2025 | Urogen PharmaURGN, 2025 |
|---|---|---|
| Revenue | $62.9m | $110m |
| Revenue growth | 699.0% | 21.4% |
| Net income | −$205m | −$153m |
| Operating margin | -338.7% | -113.7% |
| Net margin | -325.3% | -139.8% |
| Return on equity | -53.2% | — |
| Free cash flow | −$181m | −$163m |
| Cash | $164m | $111m |
| Total debt | $52.9m | $125m |
| Debt to equity | 17.3% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 298 | 291 |
| Market value | $1.61bn | $1.68bn |
| Price vs our value range | — | — |
| Moat score | — | 25 (Weak) |
| Insider trades, 12 months | 1 buys, 16 sales | 0 buys, 15 sales |